Scientific Program

Thursday, April 6 2017

8:15 - 8:30 am Welcome Address

Jean-Charles Soria, Roman Thomas, Reinhard Büttner, Jürgen Wolf

8:30 - 10:30 am Session I: Clonal Heterogenity and Resistance

Chairs: Reinhard Büttner / Pasi Jänne

8:30 - 9:00 am Functional genomics through in vivo genome editing

Monte Winslow (Stanford, US)

9:00 - 9:30 am Tracking clonal evolution to understand resistance

Martin Peifer (Cologne, DE)

9:30 - 10:00 am Resistance to next-generation EGFR-inhibitors: consequences for clinical trial design

Rafael Rosell (Barcelona, ES)

10:00 - 10:30 am Overcoming resistance to targeted drugs: the clinical perspective

Rafael Rosell (Barcelona, ES)

10:30 - 11:00 am Coffee Break
11:00 - 1:00 pm Session II: Undruggable Mutations

Chairs: Roman Thomas / Rafael Rosell

11:00 - 11:30 am Targeting Drug Resistance with Covalent Inhibitors: A Structure-Based Design Approach

Daniel Rauh (Dortmund, DE)

11:30 - 12:00 pm Targeting KRAS in murine models for synthetic letality

Christian Reinhardt (Cologne, DE)

12:00 - 12:30 pm Treating KRAS mutated NSCLC: the clinical perspective

Pasi Jänne (Boston, US)

12:30 - 1:00 pm Perspective on clinical management of challenging patients: illustration by a real-life case

Enriqueta Felip (Barcelona, ES)

1:00 - 2:00 pm Lunch
2:00 - 4:30 pm Session III: Personalized Immunotherapy

Chairs: Jürgen Wolf

2:00 - 2:30 pm Preclinical models to evaluate immune-checkpoint inhibitors

Kwok-Kin Wong (Boston, US)

2:30 - 3:00 pm Plasticity of the immunesystem and response to immunotherapy

Michael Hölzel (Bonn, DE)

3:00 - 3:30 pm Genetic determinants of sensitivity and resistance to immuno-related therapies

Montse Sanchez-Cespedes (Barcelina, ES)

3:30 - 4:00 pm Developing personalized vaccine immunotherapy

Jean-Charles Soria (Paris, FR)

4:00 - 4:30 pm Perspective on clinical management of challenging patients: illustration by a real-life case

Egbert Smit (Amsterdam, NL)

Giorgio Scagliotti (Torino, IT)

4:30 - 5:00 pm Coffee break
5:00 - 6:00 pm Session IV: Rare Mutations

Chair: Jean-Charles Soria

5:00 - 5:30 pm Combination approaches in BRAF mutant NSCLC

David Planchard (Paris, FR)

5:30 - 6:00 pm Creating evidence for the treatment of NSCLC with rare mutations

Oliver Gautschi (Luzern, CH)

6:00 - 7:00 pm Keynote Lecture: Tracking Cancer Evolution: TRACERx

Charles Swanton (London, UK)

7:30 - 11:00 pm Social Event: SkyKöln

Friday, April 7 2017

9:00 - 10:00 am Keynote Lecture: Targeting the EGFR-pathway: are we precise enough?

Pasi Jänne (Boston, US)

10:00 - 10:30 am Coffe Break
10:30 - 12:30 pm Session V: Small Cell Lung Cancer

Chairs: Christian Reinhardt / Monte Winslow

10:30 - 11:00 am Mouse models of SCLC to improve treatment efficacy

Anton Berns (Amsterdam, NL)

11:00 - 11:30 am The genomic landscape of SCLC

Julie George (Cologne, DE)

11:30 - 12:00 pm Modelling tumor progression of SCLC ex vivo

Caroline Dive (Manchester, UK)

12:00 - 12:30 pm Targeting DLL-3 in SCLC – clinical trial strategies

Laura Saunders (San Fransisco, US)

1:30 - 3:30 pm Session VI: Innovative Diagnostics

Chairs: Martin Sos / Caroline Dive

1:30 - 2:00 pm Theoretical value of liquid biopsies

Fabrice Barlesi (Marseille, FR)

2:00 - 2:30 pm Liquid biopsies: the clinical experience

Benjamin Besse (Paris, FR)

2:30 - 3:00 pm Non-structural DNA changes in NSCLC: methylation and acetylation

Ramaswamy Govindan (St. Louis, US)

3:30 - 4:00 pm Concluding Remarks

Jean-Charles Soria, Roman Thomas, Reinhard Büttner, Jürgen Wolf